ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31

ANI PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$72.56+0.27 (+0.37%)

Close on Oct 19, 2026

Market cap: $1.59B
P/E (TTM): 15.4
Dividend yield: –

ANI PHARMACEUTICALS INC balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Cash & Equivalents	286	145	221	48	100	7.86	62	43	31	27	155	169	11	0.01	0	38	30	12
Cash & Short-Term Investments	286	145	221	48	100	7.86	62	43	31	27	155	169	11	0.01	0	38	30	12
Receivables	281	222	162	165	129	96	72	65	59	46	22	17	13	5.43	–	–	–	–
Inventory	143	137	111	105	82	61	48	41	38	26	13	7.52	3.52	2.81	–	–	–	–
Prepaid Expenses & Other	34	18	17	8.39	7.59	5.86	4.00	4.52	2.78	3.56	1.45	1.14	0.58	0.31	0.80	2.47	–	–
Total Current Assets	753	528	520	344	322	170	188	153	132	103	193	195	28	8.57	58	41	–	–
Property, Plant & Equipment	62	57	45	43	53	41	41	38	20	11	7.13	5.22	4.54	4.88	0.86	0.64	–	–
Gross Property, Plant & Equipment	–	–	78	76	76	59	53	46	27	16	12	9.02	7.73	7.54	1.29	–	–	–
Accumulated Depreciation	–	–	-33	-33	-23	-18	-13	-8.40	-6.59	-5.39	-4.45	-3.79	-3.20	-2.66	-0.43	–	–	–
Land	–	–	–	–	–	–	–	–	–	–	–	–	–	0.09	–	–	–	–
Buildings & Improvements	–	–	–	–	–	–	–	–	–	–	–	–	–	3.68	–	–	–	–
Machinery & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	–	3.56	–	–	–	–
Construction in Progress	–	–	–	–	–	–	–	–	–	–	–	–	–	0.21	–	–	–	–
Long-Term Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	3.41	3.41	3.41	–	–
Operating Lease Right-of-Use Assets	–	–	–	–	–	–	–	0.50	–	–	–	–	–	–	–	–	–	–
Goodwill	62	60	28	28	28	3.58	3.58	3.58	1.84	1.84	1.84	1.84	1.84	0	–	–	–	–
Intangible Assets	480	542	209	252	294	189	180	202	230	176	66	42	10	0.09	–	–	–	–
Deferred Tax Assets	69	85	91	81	68	52	38	28	23	26	17	15	0	–	–	–	–	–
Other Long-Term Assets	14	12	12	11	2.21	0.80	1.22	1.47	0.83	0	–	–	–	0.30	–	–	–	–
Total Assets	1,440	1,284	904	760	772	461	457	431	412	323	285	260	45	14	62	45	–	–
Accounts Payable	63	46	37	29	23	11	15	8.88	3.63	3.39	2.07	2.65	1.43	1.99	3.15	4.86	–	–
Accrued Expenses	17	14	5.61	5.39	7.65	2.46	2.36	1.71	1.57	0.93	0.62	0.57	0.33	0.93	–	–	–	–
Current Portion of Long-Term Debt	17	9.17	0.85	0.85	0.85	13	9.94	3.26	3.35	0	–	–	–	–	–	–	–	–
Current Debt	17	9.17	0.85	0.85	0.85	13	9.94	3.26	3.35	0	–	–	–	–	–	–	–	–
Current Portion of Leases	1.92	1.80	1.56	0.68	0.39	0.13	0.20	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	2.24	5.62	8.16	0	0	3.91	0	5.02	0	2.40	0	4.25	0.02	–	–	–	–	–
Deferred Revenue (Current)	–	–	0	0	0.10	0.08	0.45	0.71	0	0	–	–	–	–	–	–	–	–
Total Current Liabilities	278	194	145	99	88	79	62	166	39	32	12	13	3.54	7.71	7.23	8.18	–	–
Long-Term Debt	292	309	285	286	287	172	176	67	70	0	–	–	–	–	–	–	–	–
Long-Term Leases	9.17	4.39	4.11	1.38	1.00	0.17	0.29	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	11	6.19	5.67	2.07	1.38	0.30	0.49	0.50	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	12	5.78	4.81	1.38	7.80	14	6.51	0.50	0	–	–	–	–	–	–	–	–	–
Total Liabilities	900	856	447	422	413	265	244	233	237	153	125	120	3.54	11	25	26	–	–
Total Debt	309	318	286	287	287	186	186	71	73	0	–	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	–	–	0	0	0	0	0	0	0	0	–	–	–	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–
Additional Paid-In Capital	596	520	514	404	388	214	201	187	179	173	164	160	90	1.08	–	–	–	–
Retained Earnings	-23	-100	-80	-97	-48	-4.97	18	11	-4.01	-2.92	-4.35	-20	-48	-44	-217	-166	–	–
Treasury Stock	-33	-21	-10	-5.09	-3.14	-2.25	-0.72	-0.66	-0.26	0	–	0	-0.07	0	–	–	–	–
Comprehensive Income & Other	1.03	5.34	8.86	12	-3.06	-11	-4.87	-0.38	0	–	–	–	–	–	–	–	–	–
Shareholders' Equity	541	404	433	314	334	196	213	197	175	170	160	140	41	-43	-34	19	16	14
Total Equity	541	404	433	314	334	196	213	197	175	170	160	140	41	-43	-34	19	16	14
Total Liabilities & Equity	1,440	1,284	904	760	772	461	457	431	412	323	285	260	45	14	62	45	–	–
Shares Outstanding(shares)	22	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 60.4%
Operating margin: 15.4%
Net margin: 11.1%
Return on equity, FY2025: 16.6%

Financial strength

Current ratio: 2.91
Debt to equity: 0.50
Debt to assets: 20.2%
Cash to current liabilities: 127.0%

Valuation

P/E ratio: 15.4
Price to sales: 1.63
Price to book: 2.66
Dividend yield: –